29 June 2020 : Laboratory Research
[Retracted: 07 Feb 2023] WNT974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/β-Catenin Signaling
Senmin Chen1A, Xiuli Yuan1B, Huanli Xu1C, Meng Yi1E, Sixi Liu1G*, Feiqiu Wen1FDOI: 10.12659/MSM.923799
Med Sci Monit 2020; 26:e923799
Abstract
BACKGROUND: Upregulation of the Wnt/β-catenin pathway has been demonstrated to promote tumor proliferation and chemoresistance in lymphoma. Our objective was to evaluate the effect of the Wnt/β-catenin pathway inhibitor WNT974 in lymphoma cells.
MATERIAL AND METHODS: Human lymphoma cell lines HUT-78 and BJAB were treated with or without 1 μM WNT974±0.15 μg/L doxorubicin (Dox). Cell viability and proliferation were evaluated by CCK-8 and colony formation assay. Expression of proliferating cell nuclear antigen (PCNA), KI67, and apoptotic-related proteins including Bcl-2, Bax, cleaved-caspase3, and cleaved-caspase9, together with Wnt pathway proteins Wnt, β-catenin, Axin2, and c-Myc, were detected by Western blot analysis. Flow cytometry was used to calculate the ratio of apoptotic cells.
RESULTS: In HUT-78 and BJAB cells, 1 μM WNT974 significantly reduced viability and colony formation. The expression of 2 markers of tumor cell proliferation, protein PCNA and KI67, was also reduced by WNT974. Treatment with 1 μM WNT974 for 48 h increased the rate of cell apoptosis, inhibited the expression of anti-apoptotic protein Bcl-2, and enhanced pro-apoptotic proteins Bax, cleaved-caspase3, and cleaved-caspase9 expression in both cell lines. After treatment with WNT974 plus Dox, cell viability was markedly decreased compared with Dox treatment alone. Mechanistically, WNT974 prevented the expression of Wnt, Axin2, β-catenin, and its target gene c-Myc.
CONCLUSIONS: WNT974 effectively treats lymphoma by inhibiting cell proliferation, inducing cell apoptosis, and enhancing chemosensitivity to Dox, and these effects are dependent on blocking Wnt/β-catenin signaling.
Keywords: Retracted Publication
Retraction note
- Download PDF
- Order reprints
- Export Article
- Related articles
- Share by email
- Metrics
2,374 13
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
09 Apr 2024 : Clinical Research
Correlation between Thalamocortical Tract and Default Mode Network with Consciousness Levels in Hypoxic-Isc...Med Sci Monit In Press; DOI: 10.12659/MSM.943802
19 Apr 2024 : Clinical Research
Comparative Analysis of Postoperative Sagittal Balance in Expansive Open-Door Laminoplasty versus Laminecto...Med Sci Monit In Press; DOI: 10.12659/MSM.943057
20 Mar 2024 : Clinical Research
Prevalence and Management of Chronic Pain, Including Neuropathic Pain, in Dialysis Patients with End-Stage ...Med Sci Monit In Press; DOI: 10.12659/MSM.943808
15 Mar 2024 : Clinical Research
Impact of Cluster Nursing Intervention on ICU Patients' Psychological Well-Being and Complications Associat...Med Sci Monit In Press; DOI: 10.12659/MSM.942855
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952